Visterra Licenses Dengue IP From MIT, Tops Off Series A To $34.2 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech plans to file an IND for its lead antibody candidate in seasonal and pandemic flu in early 2014. It also will optimize MIT research into dengue virus to find a clinical candidate to treat dengue fever.